CalciMedica, Inc. (CALC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
CalciMedica, Inc. (CALC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001534133 false 0001534133 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2
How this was made
The 30-second read
Why it matters
The filing updates board size (7 to 8), appoints a new director effective immediately, and describes his compensation/vesting; it also notes Fred Middleton’s retirement at the 2026 annual meeting.
Market read
Primarily governance/compensation disclosure; potential minor sentiment impact ahead of proxy/annual meeting, but no new business catalyst is stated.
What to watch
Traders should watch for any subsequent 8-K/DEF 14A details around committee assignments, director qualifications, or changes in compensation policy that could affect proxy voting sentiment.
Background
This is an SEC Form 8-K (Item 5.02) reporting board composition changes: adding a director and a planned retirement.
Ticker impact
CalciMedica appointed Evgeny Zaytsev as a new Class I director and set his $40,000 annual retainer plus a 20,000-share option.
Low likelihood of a sustained price move; any reaction is likely modest and short-lived.
The 8-K discloses a routine director appointment/retirement and standard compensation terms, with no operational, financial, or strategic decision disclosed.
Market effects
Minimal; director appointment does not signal a sector-wide regulatory or clinical shift in the text.
None indicated; company-specific governance filing.
None indicated.
Counterpoint
The appointment could be a signal of upcoming strategic/clinical focus, but the filing provides no such specifics, so the market may overreact initially.
Key entities
- issuerCalciMedica, Inc.
Nasdaq-listed company filing the 8-K about director/officer changes.
- directorEvgeny Zaytsev, M.D., Ph.D.
Appointed as a Class I director effective July 2, 2026; receives $40,000 annual retainer and a 20,000-share option vesting monthly over three years.
- directorFred Middleton
Announced retirement from the board effective at the 2026 annual meeting; no disagreement stated.
